XOMA Royalty (XOMA) Receivables (2010 - 2026)
XOMA Royalty's (XOMA) quarterly Receivables came in at $4.6 million in Q1 2026, down 17.12% year-on-year from $5.5 million in Q1 2025, and down 6.15% quarter-over-quarter from $4.9 million in Q4 2025.
XOMA Royalty (XOMA) Receivables (2010 - 2026) Analysis & Trends
XOMA Royalty has disclosed Receivables across 17 years of filings, most recently posting $4.6 million for Q1 2026.
- Receivables for Q1 2026 came in at $4.6 million, down 17.12% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.6 million (down 17.12% YoY), and the FY2025 annual result was $4.9 million, down 49.73% from the prior year.
- Receivables came in at $4.6 million for Q1 2026 at XOMA Royalty, down from $4.9 million in the prior quarter.
- In the past five years, Receivables ranged from a high of $14.8 million in Q2 2024 to a low of $6000.0 in Q1 2023.
- The 5-year median for Receivables is $2.4 million (2022), against an average of $3.3 million.
- Across the five-year window, Receivables sank 96.91% in 2022 and jumped 49950.0% in 2024, its largest moves.
- XOMA Royalty's Receivables stood at $2.4 million in 2022, then slumped by 58.18% to $1.0 million in 2023, then surged by 870.02% to $9.7 million in 2024, then slumped by 49.73% to $4.9 million in 2025, then decreased by 6.15% to $4.6 million in 2026.
- The last three Receivables figures came in at $4.6 million (Q1 2026), $4.9 million (Q4 2025), and $3.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 13.10 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 2.00 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | - |
| 10 | XOMA Royalty | 5.52 Mn | -60.56 Mn | - | 4.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.60 Mn |
| Dec 31, 2025 | 4.90 Mn |
| Sep 30, 2025 | 3.57 Mn |
| Jun 30, 2025 | 1.82 Mn |
| Mar 31, 2025 | 5.54 Mn |
| Dec 31, 2024 | 9.74 Mn |
| Sep 30, 2024 | 1.05 Mn |
| Jun 30, 2024 | 14.83 Mn |
| Mar 31, 2024 | 3.00 Mn |
| Dec 31, 2023 | 1.00 Mn |
| Sep 30, 2023 | 43,000.00 |
| Jun 30, 2023 | 901,000.00 |
| Mar 31, 2023 | 6,000.00 |
| Dec 31, 2022 | 2.40 Mn |
| Sep 30, 2022 | 16,000.00 |
| Jun 30, 2022 | 2.51 Mn |
| Mar 31, 2022 | 25,000.00 |
| Dec 31, 2021 | 209,000.00 |
| Sep 30, 2021 | 518,000.00 |
| Jun 30, 2021 | 12,000.00 |